A phase Ib clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors.

Research output: Chapter in Book/Report/Conference proceedingMeeting abstract (Book)

Original languageEnglish
Title of host publicationJournal of Clinical Oncology
PublisherAmerican Society of Clinical Oncology
Publication statusPublished - May 2019
EventASCO Annual Meeting 2019 - Chicago, Illinois, USA, Chicago, United States
Duration: 31 May 20194 Jun 2019


ConferenceASCO Annual Meeting 2019
CountryUnited States

Cite this